Chemomab Net Income From Continuing Ops from 2010 to 2026
| CMMB Stock | USD 1.51 0.03 2.03% |
Net Loss | First Reported 2020-03-31 | Previous Quarter -2.1 M | Current Value -1.7 M | Quarterly Volatility 2.2 M |
Check Chemomab Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chemomab Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.4 K, Other Operating Expenses of 12.4 M or Research Development of 12.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.53. Chemomab financial statements analysis is a perfect complement when working with Chemomab Therapeutics Valuation or Volatility modules.
Chemomab | Net Income From Continuing Ops | Build AI portfolio with Chemomab Stock |
Analyzing Chemomab Therapeutics's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Chemomab Therapeutics's current valuation and future prospects.
Latest Chemomab Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Chemomab Therapeutics Ltd over the last few years. It is Chemomab Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Chemomab Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Chemomab Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (13,948,462) | |
| Coefficient Of Variation | (43.67) | |
| Mean Deviation | 4,370,072 | |
| Median | (11,609,000) | |
| Standard Deviation | 6,091,039 | |
| Sample Variance | 37.1T | |
| Range | 17.5M | |
| R-Value | (0.47) | |
| Mean Square Error | 30.8T | |
| R-Squared | 0.22 | |
| Significance | 0.06 | |
| Slope | (567,384) | |
| Total Sum of Squares | 593.6T |
Chemomab Net Income From Continuing Ops History
About Chemomab Therapeutics Financial Statements
Chemomab Therapeutics stakeholders use historical fundamental indicators, such as Chemomab Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Chemomab Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Chemomab Therapeutics' assets and liabilities are reflected in the revenues and expenses on Chemomab Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Chemomab Therapeutics Ltd. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -12.6 M | -13.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock:Check out the analysis of Chemomab Therapeutics Correlation against competitors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. Projected growth potential of Chemomab fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Chemomab Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Chemomab Therapeutics's market price often diverges from its book value, the accounting figure shown on Chemomab's balance sheet. Smart investors calculate Chemomab Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Chemomab Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Chemomab Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemomab Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.